KatieB 266 Report post Posted January 18 FDA has accepted the supplemental Biologics License Application (sBLA) for Tecentriq in combination with chemotherapy for the first-line treatment of people with metastatic non-squamous NSCLC who do not have EGFR or ALK genomic tumor aberrations. https://www.gene.com/media/press-releases/14773/2019-01-16/fda-accepts-genentechs-supplemental-biol 2 Tom Galli and Roz reacted to this Share this post Link to post Share on other sites
